Sign in
Active, not recruitingPhase 4

The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study

Key facts

Who runs it
The University of Hong Kong
Where
Hong Kong1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 4
People taking part
600 people, planned
Started
1 Oct 2025
Expected to end
1 Oct 2030
Type of study
Interventional, 4 groups
Treatments tested
  • Live attenuated influenza vaccine
  • Placebo nasal spray
  • recombinant hemagglutinin influenza vaccine
  • Placebo injection
Record updated
15 May 2026

Who can take part

Age
22 years to 50 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Aged 22-50 years at enrolment
  • A. Participated in the DRIVE I or DRIVE II studies (for DRIVE IIIa). OR B. Did not participate in the DRIVE I or DRIVE II study (for DRIVE IIIb) and has not received influenza vaccination in the prior two years
  • Capable of providing informed consent
  • Resident in Hong Kong in the coming 2 years

Who cannot take part

  • Currently taking medication for any condition that impairs immune system
  • Individuals who report medical conditions not suitable to receive inactivated influenza vaccines, such as:; Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine; or to a vaccine component; Moderate or severe acute illness with or without fever after any previous influenza vaccination; or; A history of Guillain-Barré syndrome (GBS) within 6 weeks of previous influenza vaccination
  • Included in one of the priority groups to receive influenza vaccination in Hong Kong (priority groups include pregnant women, long-stay residents of institutions for persons with disability, persons with chronic medical problems (chronic cardiovascular, lung, metabolic or kidney diseases, obesity (body mass index 30 or above) and chronic neurological condition ), healthcare workers or persons working in poultry, pig farming or pig slaughtering industry)
  • With diagnosed medical conditions related to their immune system
  • Individuals who report medical conditions not suitable to receive live attenuated vaccines, such as:; having asthma; having close contact with severely immunosuppressed persons who require a protected environment; or; having immunosuppressive treatment (e.g. high-dose steroid, anti-cancer drugs and radiotherapy)
  • Individuals who report medical conditions not suitable to receive intramuscular injection, such as; Bleeding disorders; Habitually taking anticoagulants (with the exception of antiplatelets such as aspirin)
  • Individuals who have any medical conditions not suitable to receive inactivated or live attenuated influenza vaccines as determined by a clinician

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study will provide novel insight into the effects of repeat influenza vaccination with Flublok and FluMist on the strength and breadth of immune responses to influenza, the mechanisms underlying heterogeneity in vaccine response and vaccine failure, and biological factors that could explain variation in influenza vaccine effectiveness.

The 4 groups in the trial

  • Arm 1: 4 x FluMistTreatment being tested

    FluMist four times annually

    Treatment: Live attenuated influenza vaccine and Placebo injection

  • Arm 2: alternate FluMist and FlublokTreatment being tested

    Alternating FluMist and Flublok annually

    Treatment: Live attenuated influenza vaccine, Placebo nasal spray, recombinant hemagglutinin influenza vaccine, and Placebo injection

  • Arm 3: alternating Placebo and FlublokTreatment being tested

    Alternating Placebo and Flublok annually

    Treatment: Placebo nasal spray, recombinant hemagglutinin influenza vaccine, and Placebo injection

  • Arm 4: 4 x FlublokTreatment being tested

    Flublok four times annually

    Treatment: Placebo nasal spray and recombinant hemagglutinin influenza vaccine

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study - a Randomized Controlled Trial
Record updated
15 May 2026